Optilume is a new, approved minimally invasive treatment for benign prostatic hyperplasia (BPH) and for urethral strictures.
Optilume is a new, innovative minimally invasive treatment option for both BPH and urethral strictures.
Recently approved by the U.S. Food and Drug Administration, Optilume is a unique MIST that combines mechanical dilation using a proprietary double-lobe balloon with concurrent localized delivery of paclitaxel for the treatment of LUTS secondary to BPH.
Mechanical dilation with Optilume achieves an anterior commissurotomy, while delivery of paclitaxel is intended to maintain luminal patency during healing.
Optilume is the first combination drug and device therapy offering the highest clinically reported flow rates of any minimal invasive therapy with immediate and sustained improvement in IPSS symptom scores.
The recent FDA approval and published positive data will quickly establish Optilume as a new standard for physicians and men looking for rapid and sustained results in treating LUTS caused by BPH.
Optilume is a procedure for men who desire a minimally invasive option to treat their symptoms of BPH. It provides men relief for urinary symptoms and urethral strictures.
Optilume is an attractive option for physicians and patients looking to maintain sexual function while achieving durable symptom relief and improved flow. It is also a good option for men who do not wish to undergo surgery or take medication.
Optilume is a minimally invasive treatment option for men with BPH or lower urinary tract symptoms who want to avoid surgery or medications.
Several benefits include:
Find your BPH symptom score.
Consult with our world-class medical experts within days of your call.
Optilume is a medication-coated balloon that combines specialized drug delivery technology with balloon dilation techniques.
The purpose of the treatment is to open the urethra in order to slow or stop the regrowth of strictures and help reduce symptoms of BPH.
The drug that coats the balloon is an antiproliferative medication that is used to stop urethral strictures from forming. This treatment provides relief for urinary symptoms and offers sustained results without the long-term side effects of other treatments.
The Optilume procedure is performed with light sedation and local anesthesia.
Firstly, the patient lies on their back with their legs in stirrups. The catheter is then inserted into the urethra up to the location of the prostate.
Once the catheter is set in place, a cylindrical balloon is inflated to press against the prostate tissue, creating a passageway for urine to flow through. As the balloon expands, it creates micro fissures in the tissue.
The coating of the balloon releases a therapeutic medication directly onto the fissured tissue. This medication reduces cell proliferation and fibrotic scar tissue generation, which helps relieve urinary obstruction and improves the flow of urine.
The procedure is quick and simple. The duration of the procedure should last around 15 to 20 minutes.
The procedure is minimally invasive, so little downtime is involved. Patients may resume their normal activities within a few days following the procedure.
Effective BPH symptom relief with minimally invasive and low risk treatments.
“OptilumeBPH will revolutionize prostate office-based outpatient treatment with unparalleled urinary flow rate outcome improvements and dramatically changing the patient recovery journey. I foresee this simple procedure and medicated balloon dilation becoming the new leader of outpatient MIST prostate BPH therapies.”
In July 2024, Dr Zorn and the BPH Canada team had the first global experience of office-based OptilumeBPH performed under a local-modified prostate block in Montreal, Canada.
OptilumeBPH is the newest, approved minimally invasive surgical therapy (MIST) for men with symptomatic BPH based on the pivotal trial with 5-year outcomes. Unlike other MISTS, such as REZUM (which rely on heat/steam to burn tissue requiring catheter two weeks), iTIND (temporary nitinol metal implant for one week with pressure incisions) and Urolift (permanent metallic implants to compress BPH tissue), the OptilumeBPH system is unique and completely different in speed of results, short catheterization (only two days), faster recovery (under 2-3 weeks) and no foreign implants.
The treatment involves the deployment of a medication-coated balloon at the level of the prostate, which reshapes the prostatic urethral with a taller passage (what is referred to as an anterior commissurotomy) for only 10 minutes. Similar to cardiac angioplasty and the immediate impact of reopening obstructed heart vascular flow, the Optilume rapidly restores urinary flow and has the shortest catheterization times and fastest recovery time.
Under Dr Zorn's care, all 15 cases have had successful balloon dilation delivered in under 30 minutes with no complications.
Similar to any medical procedure, there are some potential risks and side effects associated with Optilume.
However, they are typically very low in comparison to its benefits.
It is possible for some patients to experience discomfort or pain during the procedure, particularly if the catheter is inflated too tightly. Patients may also experience bleeding or bruising in the urethra or the surrounding tissue, which typically resolves on its own. In rare cases, urinary tract infections (UTI) following the procedure may occur.
A urethral stricture is the narrowing of the urethra, resulting in obstructive urinary symptoms. It can cause a variety of medical concerns in the urinary tract, such as inflammation or even infection.
The Optilume medication is an antiproliferative drug that coats the balloon in order to stop urethral strictures from forming. It does this by minimizing the overactivity of cells and the formation of scar tissue.
Men typically start to experience improvement in their symptoms over 6 to 12 weeks following the procedure.
Patients generally experience only mild to moderate discomfort during the part of the procedure when the balloon is expanded in the urethra. Other than that, the procedure is typically painless.
Only one treatment of Optilume is required to achieve urinary symptom relief.
find us
6900 Decarie Blvd Suite M270,
Montreal, Quebec
H3X 2T8, Canada
Fax: 514-370-8886
info@bphcanada.com
AR
HY
ZH-CN
EN
DE
EL
IT
FA
PT
ES
TR
JP
